Chemomab S-4 Lays Bare Scipher Merger Terms: 68% Dilution, $30M PIPE, and Contingent Value Rights

summarizeSummary

Chemomab's S-4 reveals the full terms of its merger with Scipher: Chemomab holders get 32% of the combined company (26.7% after a $30M–$50M PIPE), CVRs worth up to $50M tied to nebokitug milestones, and a board controlled 4–1 by Scipher designees. The deal is expected to close in Q4 2026. An amendment sets a formula-based exchange ratio so the combined company will have 10,000,000 shares outstanding immediately after closing, without changing the consideration or ownership allocation.

check_boxKey Events · M&A and Partnerships · CMMB

• Updated · Sep 30 · SEC 6-K

  Merger Ownership Split: 32% Chemomab / 68% Scipher

  Chemomab shareholders will own approximately 32% of the combined company immediately prior to the PIPE (26.7% after), down from 100% today. Scipher noteholders receive 6.8M shares (68%) via conversion of 2026 Notes; all Scipher common, preferred, options, and warrants are cancelled for no consideration. An amendment sets a formula-based exchange ratio so the combined company will have 10,000,000 shares outstanding immediately after closing, without changing the consideration or ownership allocation.

• Concurrent PIPE: $30M–$50M at $150M Valuation

  A syndicate led by Northpond Ventures (with Khosla Ventures, Blue Owl) committed $30M minimum, up to $50M, at a $150M pre-money valuation with 100% warrant coverage at 50% of valuation. Expected issuance: 2.0M–3.33M PIPE Shares plus equal PIPE Warrants. $10M of Pre-Closing Financing (2026 Notes) counts toward the minimum.

• CVRs: Up to $50M in Contingent Payments

  Chemomab ADS holders and vested option holders receive one CVR per share. Milestone 1: $40M upon Phase 3 initiation or disposition of nebokitug in PSC. Milestone 2: $10M upon FDA approval in any indication. CVRs are non-transferable, have no voting rights, and may never pay out.

• Scipher Material Weakness and Quest Litigation

  Scipher disclosed a material weakness in internal control over financial reporting (lack of segregation of duties in journal entry and payroll processes). Separately, Quest Diagnostics has sued Scipher for $10M; trial is tentatively set for mid-2027.

auto_awesomeAnalysis · CMMB · Life Sciences

This S-4 registration statement marks the first detailed public disclosure of the Chemomab–Scipher merger terms. Existing Chemomab shareholders will see their ownership collapse to just 32% of the combined company before the PIPE (26.7% after), a stark dilution from their current 100% stake. The deal is structured as a reverse asset acquisition with Scipher as the accounting acquirer, meaning Scipher's financials become the combined company's historical financials. The $30M–$50M PIPE at a $150M pre-money valuation with 100% warrant coverage at 50% of valuation is highly dilutive to existing holders. CVRs offer up to $50M in contingent payments tied to nebokitug milestones, but there is no guarantee of payment. The filing also discloses Scipher's material weakness in internal controls and a $10M Quest Diagnostics litigation claim. If the merger fails, Chemomab's board may pursue dissolution and liquidation — a stark alternative that underscores the existential stakes. A subsequent amendment establishes a formula-based exchange ratio that fixes the combined company's share count at 10,000,000 immediately after closing, while leaving the consideration and ownership allocation unchanged.